PeakShares LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

PeakShares LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,428 shares of the biopharmaceutical company’s stock, valued at approximately $1,102,000. Regeneron Pharmaceuticals comprises about 1.1% of PeakShares LLC’s holdings, making the stock its 24th biggest position.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Nuveen LLC raised its stake in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Dodge & Cox raised its stake in Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Regeneron Pharmaceuticals by 8,620.0% in the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock valued at $512,881,000 after purchasing an additional 656,845 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a report on Monday, May 18th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Price Performance

REGN opened at $609.94 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $506.38 and a 12 month high of $821.11. The business has a 50-day moving average of $676.81 and a two-hundred day moving average of $732.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock has a market capitalization of $64.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm posted $8.22 EPS. The company’s revenue was up 19.0% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.